These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 37174080)

  • 1. Immune Checkpoint Profiling in Humanized Breast Cancer Mice Revealed Cell-Specific LAG-3/PD-1/TIM-3 Co-Expression and Elevated PD-1/TIM-3 Secretion.
    Bruss C; Kellner K; Albert V; Hutchinson JA; Seitz S; Ortmann O; Brockhoff G; Wege AK
    Cancers (Basel); 2023 May; 15(9):. PubMed ID: 37174080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4
    Saleh R; Toor SM; Khalaf S; Elkord E
    Vaccines (Basel); 2019 Oct; 7(4):. PubMed ID: 31614877
    [No Abstract]   [Full Text] [Related]  

  • 3. The effect of Curcumin on multi-level immune checkpoint blockade and T cell dysfunction in head and neck cancer.
    Liu L; Lim MA; Jung SN; Oh C; Won HR; Jin YL; Piao Y; Kim HJ; Chang JW; Koo BS
    Phytomedicine; 2021 Nov; 92():153758. PubMed ID: 34592487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dysregulation of systemic soluble immune checkpoints in early breast cancer is attenuated following administration of neoadjuvant chemotherapy and is associated with recovery of CD27, CD28, CD40, CD80, ICOS and GITR and substantially increased levels of PD-L1, LAG-3 and TIM-3.
    Rapoport BL; Steel HC; Benn CA; Nayler S; Smit T; Heyman L; Theron AJ; Hlatshwayo N; Kwofie LLI; Meyer PWA; Anderson R
    Front Oncol; 2023; 13():1097309. PubMed ID: 37064132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer.
    Mollavelioglu B; Cetin Aktas E; Cabioglu N; Abbasov A; Onder S; Emiroglu S; Tükenmez M; Muslumanoglu M; Igci A; Deniz G; Ozmen V
    World J Surg Oncol; 2022 Oct; 20(1):349. PubMed ID: 36271406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant radiotherapy in ER
    Bruss C; Albert V; Seitz S; Blaimer S; Kellner K; Pohl F; Ortmann O; Brockhoff G; Wege AK
    Front Immunol; 2024; 15():1355130. PubMed ID: 38742103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-L1, PD-1, LAG-3, and TIM-3 in Melanoma: Expression in Brain Metastases Compared to Corresponding Extracranial Tumors.
    Wang JJ; Burger P; Taube J; Soni A; Chaichana K; Sheu M; Belcaid Z; Jackson C; Lim M
    Cureus; 2019 Dec; 11(12):e6352. PubMed ID: 31938638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Checkpoint molecules coordinately restrain hyperactivated effector T cells in the tumor microenvironment.
    Yang M; Du W; Yi L; Wu S; He C; Zhai W; Yue C; Sun R; Menk AV; Delgoffe GM; Jiang J; Lu B
    Oncoimmunology; 2020; 9(1):1708064. PubMed ID: 32076578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TIM-3 expression in breast cancer.
    Burugu S; Gao D; Leung S; Chia SK; Nielsen TO
    Oncoimmunology; 2018; 7(11):e1502128. PubMed ID: 30377566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TIMELESS upregulates PD-L1 expression and exerts an immunosuppressive role in breast cancer.
    Dong X; Dai H; Lin Y; Sheng X; Li Y; Wang Y; Zhang X; Jiang S; Yin W; Lu J
    J Transl Med; 2023 Jun; 21(1):400. PubMed ID: 37340461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Presence of Tim3
    Klapholz M; Drage MG; Srivastava A; Anderson AC
    J Pathol; 2022 Jun; 257(2):186-197. PubMed ID: 35119692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer.
    Sasidharan Nair V; El Salhat H; Taha RZ; John A; Ali BR; Elkord E
    Clin Epigenetics; 2018; 10():78. PubMed ID: 29983831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma.
    Jing W; Gershan JA; Weber J; Tlomak D; McOlash L; Sabatos-Peyton C; Johnson BD
    J Immunother Cancer; 2015; 3(1):2. PubMed ID: 25614821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined inhibition of PD-1/PD-L1, Lag-3, and Tim-3 axes augments antitumor immunity in gastric cancer-T cell coculture models.
    Mimura K; Kua LF; Xiao JF; Asuncion BR; Nakayama Y; Syn N; Fazreen Z; Soong R; Kono K; Yong WP
    Gastric Cancer; 2021 May; 24(3):611-623. PubMed ID: 33611641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered expression of TIM-3, LAG-3, IDO, PD-L1, and CTLA-4 during nimotuzumab therapy correlates with responses and prognosis of oral squamous cell carcinoma patients.
    Wang H; Mao L; Zhang T; Zhang L; Wu Y; Guo W; Hu J; Ju H; Ren G
    J Oral Pathol Med; 2019 Sep; 48(8):669-676. PubMed ID: 31132187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The immune checkpoint molecules PD-1, PD-L1, TIM-3 and LAG-3 in diffuse large B-cell lymphoma.
    Chen BJ; Dashnamoorthy R; Galera P; Makarenko V; Chang H; Ghosh S; Evens AM
    Oncotarget; 2019 Mar; 10(21):2030-2040. PubMed ID: 31007846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blockade of PD-1, PD-L1, and TIM-3 Altered Distinct Immune- and Cancer-Related Signaling Pathways in the Transcriptome of Human Breast Cancer Explants.
    Saleh R; Toor SM; Al-Ali D; Sasidharan Nair V; Elkord E
    Genes (Basel); 2020 Jun; 11(6):. PubMed ID: 32616706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LAG-3+ tumor infiltrating lymphocytes in breast cancer: clinical correlates and association with PD-1/PD-L1+ tumors.
    Burugu S; Gao D; Leung S; Chia SK; Nielsen TO
    Ann Oncol; 2017 Dec; 28(12):2977-2984. PubMed ID: 29045526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Profiling the dynamic expression of checkpoint molecules on cytokine-induced killer cells from non-small-cell lung cancer patients.
    Zhang L; Wang J; Wei F; Wang K; Sun Q; Yang F; Jin H; Zheng Y; Zhao H; Wang L; Yu W; Zhang X; An Y; Yang L; Zhang X; Ren X
    Oncotarget; 2016 Jul; 7(28):43604-43615. PubMed ID: 27283895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging immune checkpoints for cancer therapy.
    Li X; Hu W; Zheng X; Zhang C; Du P; Zheng Z; Yang Y; Wu J; Ji M; Jiang J; Wu C
    Acta Oncol; 2015 Nov; 54(10):1706-13. PubMed ID: 26361073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.